Medical Dialogues
  • Dermatology
Sign in Signup
This site is intended for healthcare professionals only
Sign in Signup
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
Medical Dialogues
  • Medical News
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Medical Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
  • MDTV
      • Anesthesia
      • CTVS
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • Diet and nutrition
      • ENT
      • Gastroenterology
      • Health Dialogues
      • Health News today
      • Health Shorts
      • Health Updates
      • Health video of the day
      • Laboratory Medicine
      • Latest Videos
      • Latest Webinars
      • MD shorts
      • Medical News Today
      • Medical Updates
      • Medical Video of the day
      • Medicine
      • Nephrology
      • Neurology and Neurosurgery
      • Obstetrics and Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics & Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Top Videos
      • Urology
This site is intended for healthcare professionals only
Sign InRegister
Medical Dialogues
Sign inRegister
  • Home
  • Medical news
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Medical Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
  • Case of the Day
  • Editorial
  • Home
  • Cardiology-CTVS
  • Cardiology & CTVS Perspective
  • TCT 2021: CABG...

TCT 2021: CABG "remains the treatment of choice" for three-vessel coronary disease

Harinder Singh BediBy Harinder Singh BediPublished On 2021-11-10T09:15:20+05:30  |  Updated On 2021-11-10T09:19:25+05:30
TCT 2021: CABG remains the treatment of choice for three-vessel coronary disease

Percutaneous coronary intervention (PCI) guided by the ideal method ie fractional flow reserve (FFR) using the current best stent (durable polymer zotarolimus-eluting stents - Resolute Integrity or Resolute Onyx, Medtronic)did not meet non-inferiority for one-year adverse events compared to coronary artery bypass grafting (CABG) in patients with three-vessel coronary artery disease,...

Percutaneous coronary intervention (PCI) guided by the ideal method ie fractional flow reserve (FFR) using the current best stent (durable polymer zotarolimus-eluting stents - Resolute Integrity or Resolute Onyx, Medtronic)did not meet non-inferiority for one-year adverse events compared to coronary artery bypass grafting (CABG) in patients with three-vessel coronary artery disease, primary results of the FAME 3 (Fractional flow reserve versus angiography for multivessel evaluation) trial have shown.

It has been shown in innumerable studies and trials that patients with three-vessel coronary artery disease have been known to have better outcomes with coronary artery bypass grafting (CABG) than patients with percutaneous coronary intervention (PCI). However, studies in which PCI is guided by the measurement of fractional flow reserve (FFR) have been lacking.

In this multicenter, international, noninferiority trial, patients with three-vessel coronary artery disease were randomly assigned to undergo CABG or FFR-guided PCI with current-generation zotarolimus-eluting stents. The primary endpoint was the occurrence within 1 year of a major adverse cardiac or cerebrovascular event, defined as death from any cause, myocardial infarction, stroke, or repeat revascularization.

The results were presented recently during a late-breaking trial session at the Transcatheter Cardiovascular Therapeutics annual meeting (TCT 2021, 4–6 November, Orlando USA and virtual) by William Fearon (Stanford University School of Medicine, Department of Medicine, Stanford Cardiovascular Institute, Stanford, USA) and published simultaneously in the New England Journal of Medicine. Fearon told TCT attendees that in patients with more complex, three-vessel coronary artery disease, CABG remains the treatment of choice

A total of 1,500 patients were randomized 1:1 to either CABG based on coronary angiogram or FFR-guided PCI in all lesions with an FFR ≤0.80 at 48 centers in Europe, North America, Australia, and Asia. For inclusion in the trial, patients had three-vessel CAD, defined as ≥50% diameter stenosis by visual estimation in each of the three major epicardial vessels, but not involving the left main coronary artery, and amenable to revascularisation by both PCI and CABG as determined by the heart team. A total of 757 patients underwent FFR-guided PCI and 743 received CABG.

The primary endpoint of the one-year rate of death, myocardial infarction, stroke, and repeat revascularization (MACCE) was 10.6% for PCI and 6.9% for CABG (hazard ratio [HR] 1.5, 95% CI 1.1‒2.2, p=0.35 for non-inferiority). The one-year rate of death (1.6% vs. 0.9%), MI (5.2% vs. 3.5%), and stroke (0.9% vs. 1.1%) were not significantly different between the two strategies. Repeat revascularization (5.9% vs. 3.9%) was higher in the PCI group.

When patient data were analyzed based on SYNTAX score, the one-year MACCE rate was higher with PCI compared with CABG for both intermediate (13.7% vs. 6.1%) and high SYNTAX scores (12.1% vs. 6.6%) with p for interaction by SYNTAX score=0.02.

Dr. Fearon concluded that - "In patients with more complex three-vessel coronary artery disease, CABG remains the treatment of choice. If you have the more complex disease, at least based on the outcomes here—which included repeat revascularisation—bypass outperformed PCI."

It may additionally be noted that the surgery was not the off-pump or beating heart (which has been shown to give better results and is used extensively by Indian surgeons) and the trial excluded left main stenosis patients. So as per this latest study, CABG remains the clear-cut procedure of choice. In my opinion, it is not at all that surprising. In fact, it is very consistent with what other studies have shown, that for three-vessel disease, surgery tends to have the edge, even when pitted against FFR-guided PCI. In FAME-3, the 1-year follow-up was the best chance for FFR-PCI to be non-inferior to CABG but it did not happen so. The CABG advantage is only going to get better with time.

Ref: Fractional Flow Reserve–Guided PCI as Compared with Coronary Bypass Surgery. William F. Fearon, M.D., Frederik M. Zimmermann, M.D., Bernard De Bruyne, M.D., et al., for the FAME 3 Investigators*

NEJM, November 4, 2021. DOI: 10.1056/NEJMoa2112299

Disclaimer: The views expressed in the above article are solely those of the author/agency in his/her private capacity and DO NOT represent the views of Medical Dialogues.

Read website full disclaimer here

three vessel coronary disease CABG tct 2021 
Harinder Singh Bedi
Harinder Singh Bedi

    Dr. Bedi is one of the senior-most heart surgeons of India and has special expertise in bypass surgery. He is credited with one of the world’s first series of multivessel beating heart surgery with post-op check angios.

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Review: Efficacy of Antiviral Agents Against  Omicron Subvariant BA.2

    Review: Efficacy of Antiviral Agents Against Omicron Subvariant BA.2

    Choice of Antibiotics in Common Infections: Doxycycline or Azithromycin?

    Choice of Antibiotics in Common Infections: Doxycycline or Azithromycin?

    Role of acyclovir in Management of chickenpox: Analyzing the importance of starting early

    Role of acyclovir in Management of chickenpox: Analyzing the importance of starting early

    Parkinsonism and the place of Amantadine - Review Analysis

    Parkinsonism and the place of Amantadine - Review Analysis

    When to Introduce time tested drug Amlodipine to manage Hypertension?

    When to Introduce time tested drug Amlodipine to manage Hypertension?

    View All

    Journal Club Today

    Coffee brewing method, causitive factor of raised cholesterol

    Coffee brewing method, causitive factor of raised cholesterol

    View All

    Health News Today

    Health Bulletin 16/May/2022

    Health Bulletin 16/May/2022

    View All
    © 2019 All Rights Reserved.
    Powered By: Hocalwire
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
    X
    X